Artificial intelligence (AI) is transforming industries, including pharmaceuticals. Its capability to enhance drug discovery enables swift compound identification, significantly accelerating the traditional approach to developing new therapies and medicines. From molecule discovery to refining validation processes, AI's applications in drug development appear boundless. The global AI market in this field is projected to expand at a 29.7% CAGR by 2030.
Absci Corporation (ABSI), a biotech company in this niche, pioneers AI-driven drug development through its Integrated Drug Creation platform. By leveraging extensive datasets, advanced AI algorithms, and rigorous wet lab validation, it rapidly produces high-quality drug candidates, significantly lowering costs and enhancing research success.
